Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary

Joshua A. Copel; Lawrence D. Platt; John C. Hobbins; Yalda Afshar; Olga Grechukhina; Divya Mallampati; Bryann Bromley; Aaron B. Caughey; William Grobman; Christina S. Han; Kypros Nicolaides; Christian Pettker; George Saade; Baha Sibai; Hygrav Simhan; Jiri Sonek; Erika Werner; Nancy Chescheir

doi:10.1097/AOG.0000000000003582

Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary

Joshua A. Copel^*, Lawrence D. Platt, John C. Hobbins, Yalda Afshar, Olga Grechukhina, Divya Mallampati, Bryann Bromley, Aaron B. Caughey, William Grobman, Christina S. Han, Kypros Nicolaides, Christian Pettker, George Saade, Baha Sibai, Hygrav Simhan, Jiri Sonek, Erika Werner, Nancy Chescheir

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Preeclampsia is responsible for significant maternal and neonatal morbidity and is associated with a substantial economic burden. Aspirin has been shown to be effective in decreasing the risk of preterm preeclampsia; however, there is no consensus on the target population for aspirin prophylaxis. In May 2018, the Gottesfeld-Hohler Memorial Foundation organized a working group meeting with the goal of identifying the optimal preeclampsia risk-assessment strategy and consequent intervention in the United States. The meeting brought together experts from the leading professional societies. We discussed available literature and trends in preeclampsia risk assessment, current professional guidelines for identifying women at risk for preeclampsia, prophylactic use of aspirin in the United States and Europe, cost-effectiveness data, and feasibility of implementation of different assessment tools and preventive strategies in the United States. We identified specific knowledge gaps and future research directions in preeclampsia risk assessment and prevention that need to be addressed before practice change.

Original language	English (US)
Pages (from-to)	36-45
Number of pages	10
Journal	Obstetrics and gynecology
Volume	135
Issue number	1
DOIs	https://doi.org/10.1097/AOG.0000000000003582
State	Published - Jan 1 2020

Funding

This meeting was sponsored by the Gottesfeld-Hohler Memorial Foundation. Preeclampsia research is supported through many private grants and institutes at the National Institutes of Health and the NICHD. Large studies and initiatives include the NuMOM2b study (https://numom2bhhs. rti.org/Learn), the Human Placenta Project (https:// www.nichd.nih.gov/research/supported/HPP/default), and studies conducted through the Obstetric-Fetal Pharmacology Research Centers (https://www.utmb. edu/nichd-oprc/) and the Maternal Fetal Medicine Units Network (https://mfmunetwork.bsc.gwu.edu/ PublicBSC/MFMU/MFMUPublic/). Data from all NICHD-supported studies are planned to be publicly housed on a single site to facilitate access for all investigators to data and specimens at the NICHD Data and Specimen Hub (https://dash.nichd.nih.gov/).

ASJC Scopus subject areas

Obstetrics and Gynecology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/AOG.0000000000003582

Cite this

Copel, J. A., Platt, L. D., Hobbins, J. C., Afshar, Y., Grechukhina, O., Mallampati, D., Bromley, B., Caughey, A. B., Grobman, W., Han, C. S., Nicolaides, K., Pettker, C., Saade, G., Sibai, B., Simhan, H., Sonek, J., Werner, E., & Chescheir, N. (2020). Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary. Obstetrics and gynecology, 135(1), 36-45. https://doi.org/10.1097/AOG.0000000000003582

@article{f31c28aa4029469281c8c86cf5abf9a0,

title = "Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary",

abstract = "Preeclampsia is responsible for significant maternal and neonatal morbidity and is associated with a substantial economic burden. Aspirin has been shown to be effective in decreasing the risk of preterm preeclampsia; however, there is no consensus on the target population for aspirin prophylaxis. In May 2018, the Gottesfeld-Hohler Memorial Foundation organized a working group meeting with the goal of identifying the optimal preeclampsia risk-assessment strategy and consequent intervention in the United States. The meeting brought together experts from the leading professional societies. We discussed available literature and trends in preeclampsia risk assessment, current professional guidelines for identifying women at risk for preeclampsia, prophylactic use of aspirin in the United States and Europe, cost-effectiveness data, and feasibility of implementation of different assessment tools and preventive strategies in the United States. We identified specific knowledge gaps and future research directions in preeclampsia risk assessment and prevention that need to be addressed before practice change.",

author = "Copel, {Joshua A.} and Platt, {Lawrence D.} and Hobbins, {John C.} and Yalda Afshar and Olga Grechukhina and Divya Mallampati and Bryann Bromley and Caughey, {Aaron B.} and William Grobman and Han, {Christina S.} and Kypros Nicolaides and Christian Pettker and George Saade and Baha Sibai and Hygrav Simhan and Jiri Sonek and Erika Werner and Nancy Chescheir",

year = "2020",

month = jan,

day = "1",

doi = "10.1097/AOG.0000000000003582",

language = "English (US)",

volume = "135",

pages = "36--45",

journal = "Obstetrics and gynecology",

issn = "0029-7844",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

Copel, JA, Platt, LD, Hobbins, JC, Afshar, Y, Grechukhina, O, Mallampati, D, Bromley, B, Caughey, AB, Grobman, W, Han, CS, Nicolaides, K, Pettker, C, Saade, G, Sibai, B, Simhan, H, Sonek, J, Werner, E & Chescheir, N 2020, 'Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary', Obstetrics and gynecology, vol. 135, no. 1, pp. 36-45. https://doi.org/10.1097/AOG.0000000000003582

TY - JOUR

T1 - Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States

T2 - Think Tank Summary

AU - Copel, Joshua A.

AU - Platt, Lawrence D.

AU - Hobbins, John C.

AU - Afshar, Yalda

AU - Grechukhina, Olga

AU - Mallampati, Divya

AU - Bromley, Bryann

AU - Caughey, Aaron B.

AU - Grobman, William

AU - Han, Christina S.

AU - Nicolaides, Kypros

AU - Pettker, Christian

AU - Saade, George

AU - Sibai, Baha

AU - Simhan, Hygrav

AU - Sonek, Jiri

AU - Werner, Erika

AU - Chescheir, Nancy

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Preeclampsia is responsible for significant maternal and neonatal morbidity and is associated with a substantial economic burden. Aspirin has been shown to be effective in decreasing the risk of preterm preeclampsia; however, there is no consensus on the target population for aspirin prophylaxis. In May 2018, the Gottesfeld-Hohler Memorial Foundation organized a working group meeting with the goal of identifying the optimal preeclampsia risk-assessment strategy and consequent intervention in the United States. The meeting brought together experts from the leading professional societies. We discussed available literature and trends in preeclampsia risk assessment, current professional guidelines for identifying women at risk for preeclampsia, prophylactic use of aspirin in the United States and Europe, cost-effectiveness data, and feasibility of implementation of different assessment tools and preventive strategies in the United States. We identified specific knowledge gaps and future research directions in preeclampsia risk assessment and prevention that need to be addressed before practice change.

AB - Preeclampsia is responsible for significant maternal and neonatal morbidity and is associated with a substantial economic burden. Aspirin has been shown to be effective in decreasing the risk of preterm preeclampsia; however, there is no consensus on the target population for aspirin prophylaxis. In May 2018, the Gottesfeld-Hohler Memorial Foundation organized a working group meeting with the goal of identifying the optimal preeclampsia risk-assessment strategy and consequent intervention in the United States. The meeting brought together experts from the leading professional societies. We discussed available literature and trends in preeclampsia risk assessment, current professional guidelines for identifying women at risk for preeclampsia, prophylactic use of aspirin in the United States and Europe, cost-effectiveness data, and feasibility of implementation of different assessment tools and preventive strategies in the United States. We identified specific knowledge gaps and future research directions in preeclampsia risk assessment and prevention that need to be addressed before practice change.

UR - http://www.scopus.com/inward/record.url?scp=85077106723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077106723&partnerID=8YFLogxK

U2 - 10.1097/AOG.0000000000003582

DO - 10.1097/AOG.0000000000003582

M3 - Article

C2 - 31809427

AN - SCOPUS:85077106723

SN - 0029-7844

VL - 135

SP - 36

EP - 45

JO - Obstetrics and gynecology

JF - Obstetrics and gynecology

IS - 1

ER -

Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this